Clinical Trials Logo

Pulmonary Edema clinical trials

View clinical trials related to Pulmonary Edema.

Filter by:

NCT ID: NCT00627965 Completed - Clinical trials for Acute Mountain Sickness

Randomized, Controlled Trial of Regular Sildenafil Citrate in the Prevention of Altitude Illness

Start date: March 2003
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether regular oral use of sildenafil citrate can prevent or attenuate high altitude illnesses.

NCT ID: NCT00604227 Completed - Pulmonary Edema Clinical Trials

Pulmonary Function at High-Altitude

Start date: July 2005
Phase: N/A
Study type: Interventional

Based on the findings of decreased vital capacity, decreased FEV1 and increased closing volume after ascent to high altitude, some investigators suggest the presence of a subclinical high altitude pulmonary edema (HAPE). Since these parameters are only indirect measures of pulmonary interstitial fluid accumulation, the aim of this study is to examine the effects of broncho-constriction on the increase of closing volume by extensive lung function testing in healthy mountaineers at low altitude and on the Margherita Hut (4559 m). As has been done in earlier studies, conventional thorax radiographs are used for verification of HAPE. In this study, the determination of the thoracic fluid quantity will be completed by measurements of thoracic impedance. In addition markers of pulmonary endothelial function will be assessed to get further insight into the regulation of pulmonary vascular tone at altitude and in particular into the pathophysiology of HAPE.

NCT ID: NCT00559442 Completed - Clinical trials for High Altitude Pulmonary Edema

Susceptibility to High Altitude Pulmonary Edema in Subjects With Increased Hypoxic Pulmonary Vasoconstriction

Start date: June 2007
Phase: N/A
Study type: Interventional

It has been shown, that subjects susceptible to high altitude pulmonary edema (HAPE)are characterized by an abnormal increase of pulmonary artery pressure at rest in hypoxia and during exercise in normoxia. This abnormal rise of pulmonary artery pressure has also been observed in about 10 % of otherwise healthy subjects without prior altitude exposure. The aim of the study is to investigate the susceptibility to HAPE in unacclimatized subjects with abnormal increase of pulmonary artery pressure at rest in hypoxia and during exercise in normoxia after rapid ascent to high altitude (4559 m).

NCT ID: NCT00554580 Completed - Clinical trials for Congestive Heart Failure

Continuous Positive Airway Pressure for Acute Pulmonary Edema

CPAP
Start date: October 2004
Phase: Phase 3
Study type: Interventional

The investigators hypothesise that CPAP + pharmaceutical treatment, compared to pharmaceutical treatment alone, improves the respiratory and hemodynamic status of the patients before H2 after the inclusion time and decreases the rate of death and tracheal intubation during the first 48 hours.

NCT ID: NCT00513825 Completed - Clinical trials for Contrast Induced Nephropathy

Preventing Contrast Nephropathy With Sodium Bicarbonate in Patients With Pulmonary Edema,Heart Failure,Uncontrolled HTN

Start date: August 2007
Phase: Phase 2
Study type: Interventional

Radio Contrast Induced Nephropathy (RCIN) remains a well recognized complication in patients undergoing diagnostic or interventional procedures requiring radiographic contrast agents. Recent studies have shown benefit in administering Sodium Bicarbonate over normal saline( the uniformly accepted prophylaxy) in preventing RCIN.But most studies have excluded patients with history of pulmonary edema, severe heart failure(NYHA 3-4), uncontrolled hypertension or ejection fraction less than 30%. Therefore the aim of this study is to evaluate the efficacy of sodium bicarbonate solved in half saline compared with infusion of half saline in prevention of RCIN in these groups of patients.

NCT ID: NCT00453947 Completed - Clinical trials for Myocardial Infarction

Non-Invasive Ventilation in Pulmonary Edema

Start date: July 2002
Phase: Phase 4
Study type: Interventional

This randomized controlled trial is primarily aimed at assessing the rate of acute myocardial infarction with the two noninvasive ventilatory techniques, non-invasive intermittent positive pressure ventilation and non-invasive continuous positive airway pressure.

NCT ID: NCT00446498 Completed - Pulmonary Edema Clinical Trials

CPAP Versus NPPV in ACPE

Start date: July 2002
Phase: Phase 4
Study type: Interventional

To assess the intubation rate in patients affected by severe cardiogenic pulmonary edema treated with CPAP or NPPV.

NCT ID: NCT00439075 Completed - Clinical trials for Acute Cardiogenic Pulmonary Edema

OUT-OF-HOSPITAL CPAP STUDY

Start date: October 2006
Phase: Phase 4
Study type: Interventional

Evaluate efficacy and safety of CPAP in a randomised standard treatment controlled study, in out-of-hospital patients with acute cardiogenic pulmonary edema.

NCT ID: NCT00390442 Completed - Clinical trials for Cardiogenic Pulmonary Edema

Out-of-Hospital CPAP for Severe Cardiogenic Pulmonary Edema

Start date: n/a
Phase: Phase 3
Study type: Interventional

In cardiogenic pulmonary edema, Continuous Positive Airway Pressure (CPAP) added to medical treatment improves outcome. The present study was designed to assess the benefit of CPAP as a first line treatment of cardiogenic pulmonary edema in the out-of-hospital environment.

NCT ID: NCT00310401 Completed - Pulmonary Edema Clinical Trials

The Effect of Nebulized Albuterol on Donor Oxygenation

Start date: April 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the effectiveness of albuterol versus placebo with the following specific aims: a) Treatment of brain dead organ donors with albuterol will reduce pulmonary edema, improve donor oxygenation, and increase the number of lungs available for transplantation, b) Developing a blood test to predict the development of primary graft dysfunction in lung transplant recipients, and c) treating brain dead organ donors with albuterol will decrease markers of primary graft dysfunction and lead to improved lung transplant recipient outcomes and to higher rates of lungs suitable for transplantation.